$SRRK

Peng Katie sold $293K of SRRK

Peng Katie sold 5,446 shares of Scholar Rock Holding Corp (SRRK) at an average of $53.88 ($53.56–$54.96, $0.29M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Peng Katie
Published Jul 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Neutral
high confidence
Mentioned
$SRRK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKNeutralLow
01

Why it matters

Because the sale is pre-arranged and no new corporate event is disclosed, the trading signal is likely weak and mostly sentiment-driven.

02

Market read

Traders may note the insider sale, but there is no new fundamental catalyst in the text.

03

What to watch

The article provides no change in business outlook, only the transaction mechanics and post-sale holdings, limiting interpretability.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-06 for a sale executed 2026-07-01

Background

The article is an SEC Form 4 insider transaction report for Scholar Rock Holding Corp, filed after trades executed under a 10b5-1 plan.

Company-level read

Ticker impact

$SRRKNeutralHigh confidence
Context

Scholar Rock Holding Corp disclosed a director open-market sale of 5,446 shares under a 10b5-1 plan, totaling about $293K.

Expected impact

Likely minimal immediate price impact; any effect is more about sentiment than new operating information.

Evidence & confidence

Form 4 details a director’s planned sale with no accompanying guidance, deal, or regulatory/operational change described in the text.

Market effects

No sector-wide implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

A director sale can still reflect liquidity needs rather than bearish expectations, especially when executed under a 10b5-1 plan.

Key entities

  • Scholar Rock Holding Corp

    Subject of the Form 4 insider transaction disclosure.

  • Peng Katie

    Director who sold shares via an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRRKMedAI 9/10

Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

Scholar Rock Holding (SRRK) received FDA approval for ISEMBYLD, a treatment for spinal muscular atrophy in patients aged 2+. The drug showed a 2.2-point advantage over placebo in motor ability tests. The company is launching the product in the U.S., with support programs for insurance and infusions. Commercial success depends on patient access and treatment persistence, with safety concerns and reimbursement terms being key factors.

$SRRKMed

SRRK Maintained by Evercore ISI Group -- Price Target Raised to

Evercore ISI Group analyst Cory Kasimov maintained an 'Outperform' rating on Scholar Rock Holding Corp (SRRK) and raised the price target from $65.00 to $72.00, a 10.77% increase. SRRK's current price is $47.34 with a market cap of $5.77 billion. The company's GF Score™ is 29/100, indicating room for improvement in financial metrics. Insider activity shows $923,107 in sales over the last three months. The company focuses on biotechnology, developing therapies for rare neuromuscular diseases.

$SRRKHighAI 9/10

Scholar Rock wins FDA approval for spinal muscle atrophy drug

Scholar Rock received FDA approval for Isembyld, a drug targeting muscle loss in spinal muscular atrophy (SMA). The approval follows successful clinical trials showing improved motor skills in patients. The drug is approved for use with existing SMA therapies. Scholar Rock, valued at $6.8B, addressed manufacturing issues before resubmission. Pricing details are pending.